Frazier Life Sciences Management L.P. Cuts Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Frazier Life Sciences Management L.P. lowered its stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 23.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 955,515 shares of the company's stock after selling 295,271 shares during the quarter. Frazier Life Sciences Management L.P. owned 2.89% of Lexeo Therapeutics worth $6,287,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp boosted its stake in Lexeo Therapeutics by 5.6% during the 4th quarter. Bank of New York Mellon Corp now owns 50,660 shares of the company's stock worth $333,000 after purchasing an additional 2,677 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Lexeo Therapeutics by 30.1% during the 4th quarter. JPMorgan Chase & Co. now owns 13,371 shares of the company's stock worth $88,000 after purchasing an additional 3,093 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Lexeo Therapeutics by 49.9% during the 4th quarter. Wells Fargo & Company MN now owns 11,156 shares of the company's stock worth $73,000 after purchasing an additional 3,714 shares during the last quarter. Rhumbline Advisers boosted its stake in Lexeo Therapeutics by 19.6% during the 4th quarter. Rhumbline Advisers now owns 25,197 shares of the company's stock worth $166,000 after purchasing an additional 4,127 shares during the last quarter. Finally, Barclays PLC boosted its stake in Lexeo Therapeutics by 9.9% during the 4th quarter. Barclays PLC now owns 55,161 shares of the company's stock worth $363,000 after purchasing an additional 4,951 shares during the last quarter. Institutional investors and hedge funds own 60.67% of the company's stock.

Lexeo Therapeutics Trading Down 8.4%

Shares of NASDAQ LXEO traded down $0.26 during trading on Friday, hitting $2.82. 480,722 shares of the company were exchanged, compared to its average volume of 489,318. Lexeo Therapeutics, Inc. has a 12-month low of $1.45 and a 12-month high of $19.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. The company has a fifty day moving average price of $3.09 and a 200-day moving average price of $4.80. The firm has a market capitalization of $93.62 million, a PE ratio of -0.89 and a beta of 1.27.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.19). As a group, equities research analysts expect that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on LXEO. Chardan Capital lowered their target price on shares of Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Leerink Partners lowered their target price on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research note on Monday, March 24th. HC Wainwright lowered their target price on shares of Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Finally, Royal Bank of Canada lowered their target price on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 25th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $20.20.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.